Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia

by EA Stadnik, NS Timofeeva, VV Strugov, AYu Zaritskey
Published 2018-01-01

Role of Patient’s Age and Comorbidities in Therapy of Chronic Lymphocytic Leukemia

by VV Strugov, EA Stadnik, YuV Virts, TO Silina, AYu Zaritskii
Published 2016-04-01

Role of Superficial CD200 Marker in Differential Diagnosis of Malignant B-Cell Lymphoproliferative Diseases

by YuV Mirolyubova, EA Stadnik, TS Nikulina, VV Strugov, TO Andreeva, YuV Virts, RV Grozov, AYu Zaritskey
Published 2017-04-01

Effect of IGHV Gene Mutation Status and BCR Structure Stereotypy on Effectiveness of BR Regimen in First-Line Therapy of Chronic Lymphocytic Leukemia

by VV Strugov, EA Stadnik, AM Rumyantsev, TO Andreeva, YuV Virts, YuV Mirolyubova, PA Butylin, AYu Zaritskey
Published 2017-04-01

Minimal Residual Disease and IGHV-Genes Mutational Status as the Main Predictors of Response to Bendamustine-Rituximab Therapy in Previously Untreated Chronic Lymphocytic Leukemia

by YuV Mirolyubova, EA Stadnik, VV Strugov, TO Andreeva, TS Nikulina, YuV Virts, PA Butylin, AG Rumyantsev, AYu Zaritskey
Published 2018-04-01